UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 6, 2004
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
--------------------------------------------------------------------------------
Nevada 000-49616 88-0488686
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
--------------------------------------------------------------------------------
11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
--------------------------------------------------------------------------------
Registrant's telephone number, including area code (858) 794-8889
--------------
Not Applicable
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On April 6, 2004, Halozyme Therapeutics, Inc. ("Halozyme") issued a press
release that Robert Engler, M.D., had been named to its Board of Directors. In
addition, Ira Lechner, Chairman of the Board, resigned from the Board of
Directors and Jonathan Lim, M.D., Halozyme's President and Chief Executive
Officer, added the post of Chairman of the Board to his duties. The foregoing is
discussed in greater detail in such press release, a copy of which is filed
herewith as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
The following exhibit is filed with this Form 8-K.
Exhibit No. Description
----------- -----------
99.1 Press Release of April 6, 2004, regarding the
appointment of Robert Engler, M.D., to the Board of
Directors, the resignation of Ira Lechner from the
Board of Directors and the appointment of Jonathan
Lim, M.D., as Chairman of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HALOZYME THERAPEUTICS, INC.
Date: April 6, 2004 By: /s/ Jonathan E. Lim, M.D.
-------------------------------------
President and Chief Executive Officer